Mutabilis
  • About us
    • Company overview
    • Management
    • Scientific Advisory Board
    • Partners
  • R&D
    • Pipeline
  • News
  • Contact
    • Localization

  • Home
  • Blog
  • All
  • News

The World Health Organization releases a report on the clinical pipeline of antibiotics

By: admutabilis | Tags: | Comments: 0

The World Health Organization had published earlier this year a list of the most concerning pathogens. The WHO continues with a report on the pipeline of antibiotics currently in clinical development to assess how we are going to manage the pathogens of the list.

READ MORE

Mutabilis joins the European ENABLE consortium to fight antibiotic resistance (october 17th 2017).

By: admutabilis | Tags: | Comments: 0

Mutabilis has been selected by the European ENABLE project (European Gram-negative Antibacterial Engine), which aims to improve the development of antibiotics against infections caused by multiresistant Gram-negative bacteria.

READ MORE

DRIVE-AB final conference : New economic models for much needed innovative antibiotics presented at the (5-6 september 2017, Brussels). (June 1st 2017)

By: admutabilis | Tags: | Comments: 0

The DRIVE-AB project is part of the IMI’s New Drug For Bad Bugs (ND4BB) initiative

READ MORE

The European Commission has released a new action plan against Antimicrobial Resistance (AMR). (May 5th 2017)

By: admutabilis | Tags: | Comments: 0

The new European AMR plan relies on the “One Health” approach

READ MORE

The OHE report on incentives to tackle Anti-Microbial Resistance. (May 5th 2017)

By: admutabilis | Tags: | Comments: 0

The Office of Health Economic (UK) has released a report that assess the relevance

READ MORE

From April 22 to 25 2017 (Vienna)

By: admutabilis | Tags: | Comments: 0

Mutabilis will be represented at the European Congress on Clinical Microbiology and Infectious Diseases (ECCMID) in Vienne from April 22nd to 25th 2017.

READ MORE

From March 20 to 21 2017 (London)

By: admutabilis | Tags: | Comments: 0

Mutabilis will be represented at the “Superdrugs for Superbugs” conference in London on March 20th and 21st 2017.

READ MORE

The World Health Organization publish a list of the 12 most worrying pathogens. (March 1st 2017)

By: admutabilis | Tags: | Comments: 0

The Organization has published its first list of the 12 most worrying pathogens

READ MORE

From March 13 to 18, 2016 : come and meet us at the Gordon Research Conferences (Italy)

By: admutabilis | Tags: | Comments: 0

Mutabilis will be at the Gordon Research Conferences in Italy.

READ MORE

From 19 to 25 February 2016 – Come and meet us at the CROI (Boston)

By: admutabilis | Tags: | Comments: 0

Conference on Retrovirus and Opportunistic Infections.

READ MORE
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • Next »

MUTABILIS


Biocitech Park, 102 avenue Gaston Roussel, 93230 Romainville, France info@mutabilis.fr


Mutabilis is a biopharmaceutical company specialized in research and development of anti-infectious treatments.


Legal notice / Contact us